Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAXIBACUMAB vs ANTHIM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Raxibacumab is a monoclonal antibody that binds to the protective antigen (PA) component of Bacillus anthracis toxins, preventing PA from binding to host cell receptors and thereby inhibiting the intracellular entry of lethal factor and edema factor. This neutralizes the lethal and edema toxins, reducing pathogenicity.
Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.
Inhalational anthrax: Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs,Inhalational anthrax prophylaxis: Prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate
FDA: Treatment of chronic lymphocytic leukemia (CLL) (not approved; withdrawn from market),Off-label: None
Single intravenous dose of 40 mg/kg administered over 30 minutes.
800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.
Terminal elimination half-life approximately 12-24 hours (mean ~18 hours) in patients with normal renal function; half-life extends in renal impairment.
Terminal elimination half-life: approximately 21 days (range 12–31 days); supports monthly dosing for post-exposure prophylaxis
Monoclonal antibodies are generally degraded into small peptides and amino acids via catabolic pathways, similar to endogenous immunoglobulins. Raxibacumab metabolism is not mediated by hepatic CYP450 enzymes.
Metabolized by exonucleases to shorter oligonucleotides.
Primarily renal excretion as intact protein; >90% of administered dose recovered in urine over 48 hours.
Renal: approximately 50% as unchanged drug; biliary/fecal: minimal (<10%)
Negligible protein binding (<1% bound) as a monoclonal antibody.
Approximately 57% bound to plasma proteins (including albumin and immunoglobulins)
Volume of distribution approximately 0.15 L/kg, indicating limited extravascular distribution consistent with a large protein.
Volume of distribution: approximately 0.16–0.20 L/kg; indicates limited extravascular distribution, consistent with a monoclonal antibody
Intravenous: 100%; Subcutaneous: Approximately 60-70% (mean ~65%).
Intravenous: 100% bioavailability; no other routes are approved or clinically relevant
No dosage adjustment required for any degree of renal impairment including end-stage renal disease.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or ESRD.
No dosage adjustment required for any degree of hepatic impairment.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Insufficient data for severe hepatic impairment (Child-Pugh C).
Safety and efficacy in pediatric patients have not been established.
For patients weighing 10 kg to <40 kg: 14 mg/kg IV (max 800 mg) over 90 minutes, then 7 mg/kg IV (max 400 mg) over 90 minutes at 2 and 4 weeks post-first dose. For patients ≥40 kg: same as adult dosing.
No specific dosage adjustment recommended; clinical studies included limited number of patients aged 65 and older.
No specific dose adjustment recommended; clinical studies did not include sufficient numbers of patients aged ≥65 years to determine whether they respond differently. Use with caution.
None.
None.
Hypersensitivity reactions, including anaphylaxis, have been reported. Monitor patients during infusion and have appropriate medical support available.,Infusion-related reactions (e.g., urticaria, pruritus, rash) may occur. Slow or stop infusion if severe.,Interference with immune response: As a monoclonal antibody, may interfere with the immune response to anthrax vaccination. Use with caution.,Limited clinical data: Efficacy is based on animal models; clinical efficacy in humans is not established.
Myelosuppression,Infusion reactions,Tumor lysis syndrome,Electrolyte abnormalities,Cardiotoxicity
None.
Hypersensitivity to oblimersen or any component of the formulation
No known food interactions. Take with or without food.
No known food interactions. ANTHIM is administered intravenously, and food intake does not affect its pharmacokinetics.
FDA Pregnancy Category C. Animal studies show embryotoxicity at high doses; no adequate human studies. Avoid in pregnancy unless benefit outweighs risk. First trimester: potential for teratogenicity; second and third trimesters: risk of fetal hemorrhage due to antiplatelet effect.
ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data is limited. As a Ig G1 monoclonal antibody, it is expected to cross the placenta increasingly after the first trimester. The risk is likely low but cannot be excluded. Use only if clearly needed.
Unknown if excreted in human breast milk. M/P ratio not determined. Due to long half-life and potential for bleeding, caution advised; consider discontinuing breastfeeding during therapy.
It is not known whether obiltoxaximab is excreted in human milk. Monoclonal antibodies are typically excreted in breast milk at low levels with limited oral bioavailability due to gastrointestinal degradation. The M/P ratio is unknown. Caution should be exercised, but benefits of breastfeeding and maternal therapy should be considered.
No specific studies; pharmacokinetics may be altered due to increased plasma volume and renal clearance. Use lowest effective dose; consider dose reduction based on platelet count and bleeding risk.
No dose adjustment is required for ANTHIM based on pregnancy. Pharmacokinetic studies in pregnant women are not available; however, pregnancy-related changes in volume of distribution and renal clearance may alter drug levels, but clinical significance is unknown. Standard adult dosing is recommended.
Raxibacumab is a monoclonal antibody indicated for inhalation anthrax and prophylaxis when alternative therapies are unavailable. Administer intravenously over 2 hours and 15 minutes. Premedication with diphenhydramine is recommended to reduce infusion reactions. Monitor for anaphylaxis. Not effective for cutaneous anthrax. Use in pregnancy only if benefit outweighs risk.
ANTHIM (obiltoxaximab) is a monoclonal antibody indicated for inhalational anthrax. It should be administered as soon as possible after suspected or confirmed exposure. Premedication with diphenhydramine may reduce infusion reactions. Monitor for anaphylaxis and infusion-related reactions. Efficacy is established in animal models due to ethical limitations.
This medication is given as an intravenous infusion for anthrax infection or prevention.,You will receive premedication to reduce the risk of allergic reactions.,Report any symptoms of allergic reaction such as hives, itching, difficulty breathing, or swelling during infusion.,This drug is not a vaccine and does not provide long-term protection.,Complete the full course of treatment as prescribed even if you feel better.
ANTHIM is used to treat or prevent inhalational anthrax, which can be fatal if not treated.,You will receive this medication as an intravenous (IV) infusion over 1.5 hours.,You may experience side effects such as pain or swelling at the infusion site, headache, itching, or feeling tired.,Serious allergic reactions can occur; tell your healthcare provider immediately if you develop rash, hives, difficulty breathing, or swelling of the face or throat.,Because ANTHIM is made from mouse proteins, it can cause allergic reactions in some people.,This medication should not replace a recommended vaccination program for anthrax.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAXIBACUMAB vs ANTHIM, answered by our medical review team.
RAXIBACUMAB is a Monoclonal Antibody that works by Raxibacumab is a monoclonal antibody that binds to the protective antigen (PA) component of Bacillus anthracis toxins, preventing PA from binding to host cell receptors and thereby inhibiting the intracellular entry of lethal factor and edema factor. This neutralizes the lethal and edema toxins, reducing pathogenicity.. ANTHIM is a Monoclonal Antibody that works by Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAXIBACUMAB and ANTHIM depend on the specific clinical indication. These are both Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAXIBACUMAB is: Single intravenous dose of 40 mg/kg administered over 30 minutes.. The standard adult dose of ANTHIM is: 800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAXIBACUMAB and ANTHIM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAXIBACUMAB is classified as Category C. FDA Pregnancy Category C. Animal studies show embryotoxicity at high doses; no adequate human studies. Avoid in pregnancy unless benefit outweighs risk. First trimester: potential . ANTHIM is classified as Category C. ANTHIM (obiltoxaximab) is a monoclonal antibody. Embryo-fetal developmental studies in monkeys showed no adverse effects at doses up to 17 times the human dose. However, human data. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.